Most of today's gene therapies rely on viruses — and that's a problem

The next big strides in gene therapy for rare diseases may come from CRISPR and new approaches to delivery.

Related Keywords

Miami ,Florida ,United States ,Switzerland ,Ridgefield ,Pennsylvania ,Philadelphia ,Ohio ,Sarepta ,Mississippi ,University Of Miami ,Midlothian ,United Kingdom ,Columbus ,Miller School ,Milan ,Lombardia ,Italy ,London ,City Of ,Boston ,Massachusetts ,Stanford ,American ,Jesse Gelsinger ,Terry Hogan ,Sheila Ungerer ,Johns Hopkins ,Matthew Porteus ,Hamideh Parhiz ,Alfonso Sabater ,Conner Curran ,Maria Grazia Roncarolo ,Stefano Rivella ,Chris Curran ,Antonio Vento ,Miller School Of Medicine ,American Society Of Gene ,Fedex ,European Medicines Agency ,University Of Miami Health System ,Pfizer ,Bascom Palmer Eye Institute ,Old Navy ,Vertex Pharmaceuticals ,University Of Pennsylvania Perelman School Medicine ,Stanford School Of Medicine ,Telethon Institute ,Drug Administration ,Johns Hopkins University ,Third International Summit On Human Genome Editing ,San Raffaele Telethon Institute For Gene Therapy ,Will Ungerer ,Nationwide Children ,Sarepta Therapeutics ,American Society ,Garry Cutting ,Kindness Over Muscular Dystrophy ,Stanford School ,Third International Summit ,Human Genome ,Editas Medicine ,Science Translational ,Cure Rare ,New England Journal ,Pennsylvania Perelman School ,Miami Health System ,Krystal Biotech ,San Raffaele Telethon Institute ,Gene Therapy ,Victoria Gray ,